Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 1/20 | 0.47 |
| ▸ | FDPS | P14324 | 1/20 | 0.41 |
| ▸ | BLM | P54132 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | CA4 | P22748 | 1/20 | 0.32 |
| ▸ | BTN3A1 | O00481 | 2/20 | 0.31 |
| ▸ | PPARD | Q03181 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23351231 | 0.91 | FDPS (0.50) | CA2FDPSBLMTDP1CA4 | |
| SCHEMBL6364487 | 0.91 | FDPS (0.50) | CA2FDPSBLMTDP1CA4 | |
| SCHEMBL11911193 | 0.88 | FDPS (0.47) | CA2FDPSBLMTDP1CA4 | |
| SCHEMBL18650794 | 0.86 | CA2 (0.35) | CA2FDPSBLMTDP1 | |
| SCHEMBL19057264 | 0.86 | CA2 (0.35) | CA2FDPSBLMTDP1 | |
| SCHEMBL22222418 | 0.86 | CA2 (0.35) | CA2FDPSBLMTDP1 | |
| SCHEMBL3364605 | 0.85 | — | — | |
| SCHEMBL18650795 | 0.84 | CA2 (0.39) | CA2FDPSBLMTDP1 | |
| SCHEMBL412534 | 0.84 | CA2 (0.39) | CA2FDPSBLMTDP1BTN3A1 | |
| SCHEMBL19391962 | 0.84 | FDPS (0.36) | CA2FDPSBLMTDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230201207-A1 | COMBINATION CANCER THERAPY USING N2-QUINOLINE OR ISOQUINOLINE SUBSTITUTED PURINE DERIVATIVES | Shanghai Huayu Biotechnology Co., Ltd. (CN) | 2023-06-29 | — | — | US | disclosed |
| CN-115298170-A | Biaryl derivatives as inhibitors of YAP/TAZ-TEAD protein-protein interactions | 诺华股份有限公司 | 2022-11-04 | — | — | CN | disclosed |
| US-8530602-B2 | Polyether polyol composition and use thereof | ASAHI GLASS COMPANY, LIMITED (JP) | 2013-09-10 | — | — | US | disclosed |
| US-20120214888-A1 | PROCESS FOR PREPARING A POLYURETHANE FOAM | SHELL OIL COMPANY | 2012-08-23 | — | — | US | disclosed |
| US-8148349-B2 | Nucleoside cyclic phosphoramidates for the treatment of RNA-dependent RNA viral infection | ISTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P. ANGELETTI S.P.A. (IT) | 2012-04-03 | — | — | US | disclosed |
| US-20100022468-A1 | NUCLEOSIDE CYCLIC PHOSPHORAMIDATES FOR THE TREATMENT OF RNA-DEPENDENT RNA VIRAL INFECTION | MERCK SHARP & DOHME LLC | 2010-01-28 | — | — | US | disclosed |
| US-20090215935-A1 | POLYETHER POLYOL COMPOSITION AND USE THEREOF | ASAHI GLASS COMPANY, LIMITED (JP) | 2009-08-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230201207-A1 | COMBINATION CANCER THERAPY USING N2-QUINOLINE OR ISOQUINOLINE SUBSTITUTED PURINE DERIVATIVES | NME2, NTPCR, TYMP | CA2 2461/4885FDPS 2712/4885BLM 479/4885 |
| US-20100022468-A1 | NUCLEOSIDE CYCLIC PHOSPHORAMIDATES FOR THE TREATMENT OF RNA-DEPENDENT RNA VIRAL INFECTION | RNGTT, NSUN2, RNASE1 | CA2 4467/4885FDPS 350/4885BLM 2537/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.